|
|
Article: Nanotherapeutics Announces NanoBUP[TM] Capsule for Treating Opiate Addiction Demonstrated Bioavailability and Safety in Phase Ia Clinical Trial.
- Article from:
- Business Wire
- Article date:
- August 6, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Progress in other Nanotherapeutics clinical programs
NanoDOX[TM] for Diabetic Foot Ulcers Enrolling Patients at Florida VA Hospital
FDA Clearance to start Surgical Wound Healing study with Walter Reed Army Medical Center
ALACHUA, Fla. -- Nanotherapeutics, Inc., a privately held specialty biopharmaceutical company, announced that NanoBUP[TM] Oral Buprenorphine / Naloxone Capsule, for treating opiate addiction, demonstrated strong oral absorption in a Phase Ia clinical trial. The 2 x 2mg capsule achieved significant oral bioavailability of 60 to 70 percent, in comparison to sublingual administration of buprenorphine/naloxone at a similar dose, as ...